Pharmacoeconomic review report : Omalizumab (Xolair)

Pharmacoeconomic review report Omalizumab (Xolair)

Omalizumab is being reviewed for the treatment of adults and adolescents (12 years of age and older) with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen, and whose symptoms are inadequately controlled with inhaled corticosteroids...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2017.
Colección:Common drug review clinical review report.
Materias:
Antiasthmatic agents.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268606719
Tabla de Contenidos:
  • Abbreviations
  • Summary
  • Background
  • Approach to This Review
  • Cost Comparison
  • Summary of the Published Economic Information
  • New Information Since 2006
  • Issues for Consideration
  • Conclusions
  • APPENDIX 1. Cost Comparison Table
  • APPENDIX 2. Review of the Existing Literature
  • APPENDIX 3. Published Health Technology Assessment Reports
  • APPENDIX 4. Other Potential Comparator Treatments
  • References.

Ejemplares similares